Drug intelligence / Profile preview

Whole peanut extract

Development stage: Unknown
Lead developer: DBV Technologies
Modality: Recombinant Proteins and Enzymes
Administration: Epicutaneous

Overview

Whole peanut extract is a biologic preparation containing peanut proteins, developed by DBV Technologies. It is being investigated for the treatment of peanut allergy through epicutaneous immunotherapy (EPIT), where it is applied via a patch delivery system (Viaskin device) to induce desensitization to peanut allergens.

Beyond the preview

Go deeper on Whole peanut extract.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Whole peanut extract.

Explore the full profile